Laparoscopic Ileal Interposition and Weight Regain
Ileal Interposition to the Treatment of Weight Regain After Roux-en-Y Gastric Bypass: a Randomized Controlled Trial
1 other identifier
interventional
30
1 country
1
Brief Summary
The investigators will study the Ileal interposition to the treatment of weight regain after Roux-en-Y gastric bypass, assessing weight loss, body composition, quality of life, metabolic biomarkers, inflammatory biomarkers, and incretin hormones
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable obesity
Started Dec 2023
Typical duration for not_applicable obesity
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 7, 2023
CompletedFirst Posted
Study publicly available on registry
July 6, 2023
CompletedStudy Start
First participant enrolled
December 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
May 1, 2026
CompletedApril 16, 2024
April 1, 2024
2.3 years
May 7, 2023
April 14, 2024
Conditions
Outcome Measures
Primary Outcomes (2)
Changes of weight loss of participants after Ileal interposition surgery as measured by weight in kilograms
Weight loss will be obtained as the difference between preoperative weight and minimum postoperative weight in kilograms
Change from baseline and after 6 months post-surgery
Changes of Health-related quality of life of participants after Ileal interposition surgery as reported by 36-Item Short-Form Health Survey questionnaire
Health-related quality of life will be assessed using the 36-Item Short-Form Health Survey questionnaire
Change from Baseline and after 6 months post-surgery
Secondary Outcomes (8)
Changes of weight loss of participants after Ileal interposition surgery as measured by weight in kilograms
Change from baseline and after 3, 6, and 12 months post-surgery
Change of body composition of participants after Ileal interposition surgery as measured by lean and fat mass in kilograms
Change from baseline and after 6 and 12 months post-surgery
Change of metabolic profile of participants after Ileal interposition surgery as assessed by serum levels of glucose and insulin
Change from baseline and after 6 and 12 months post-surgery
Change of inflammatory biomarkers and incretin hormones of participants after Ileal interposition surgery as assessed by serum levels of tumor necrosis factor-alpha, interleukin-6, ghrelin, and glucagon-like peptide-1.
Change from baseline and after 6 months post-surgery
Changes in alcohol abuse of participants after Ileal interposition surgery as reported by Alcohol Use Disorders Identification Test
Change from baseline and after 6 and 12 months post-surgery
- +3 more secondary outcomes
Study Arms (2)
Ileal Interposition
EXPERIMENTALInterposition ileal surgery group Procedure/Surgery: Bariatric surgery
Traditional surgical technique
ACTIVE COMPARATORConventional revisional surgery group Procedure/Surgery: Bariatric surgery
Interventions
Bariatric surgery by laparoscopic Ileal Interposition
Bariatric surgery by laparoscopic traditional technique
Eligibility Criteria
You may qualify if:
- Patients submitted to initial laparoscopic after initial Roux-en-Y gastric bypass for at least 3 years
- Loss of excess weight between 60 to 80%
- Rate of weight regain ≥60%
- Body mass index ≥ 40 kg/m2 or ≥ 35 kg/m2, with at least 2 comorbidities associated with obesity
- Present a previous evaluation by the multidisciplinary team with a favorable opinion of the revision surgery.
You may not qualify if:
- Active chemical dependency on alcohol and/or illicit drugs
- Severe psychotic or depressive disorder or history of suicide attempts in the last 12 months
- Eating behavior disorder (uncontrolled)
- Secondary causes of obesity
- Pregnancy
- Severe organ failure
- Active neoplastic
- Infectious or inflammatory disease
- Severe coagulopathy
- High anesthetic-surgical risk
- Intellectual inability
- Lack of preoperative follow-up
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
State University of Rio de Janeiro
Rio de Janeiro, Brazil
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Luiz Guilherme Kraemer-Aguiar, PhD
State University of Rio de Janeiro
- PRINCIPAL INVESTIGATOR
Paulo Roberto G Falcão Leal, MD
State University of Rio de Janeiro
- PRINCIPAL INVESTIGATOR
Karynne G Grutter Lopes, PhD
State University of Rio de Janeiro
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
May 7, 2023
First Posted
July 6, 2023
Study Start
December 1, 2023
Primary Completion
April 1, 2026
Study Completion
May 1, 2026
Last Updated
April 16, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share